Clinical Trial Update: Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation [Phase 3]

View source ↗

Summary

Phase 3 trial comparing edoxaban to vitamin K antagonists in atrial fibrillation patients undergoing catheter ablation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Edoxaban (edoxaban)

Snippet

Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Conditions: Atrial Fibrillation | Phase 3 | Status: COMPLETED | Results posted: 2019-09-23